A recent study indicated that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.
Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer.
Although concurrent chemotherapy and radiation is considered standard care, treatment of locally advanced NSCLC continues to be challenging, leading researchers to search for patients who may benefit from the addition of cyclooxygenase 2 inhibitors.
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.
Data from the ongoing phase I/II ARROW clinical trial will be used to support a new drug application submission for pralsetinib to the FDA for the treatment of patients with RET fusion-positive non-small cell lung cancer.
The approach was created by the University of Michigan Rogel Cancer Center to limit variability and investigator bias.
These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.
In our lung cancer quiz, you'll get a chance to test your knowledge of the mortality risk among patients with lung cancer, and learn more about screening criteria to try reduce these rates.
Single dose radiotherapy may be as effective as 5 doses for patients with spinal canal compression from metastatic cancer.
To improve quality of life for patients with depression, researchers indicated it is crucial to provide referral and follow-up mental health care for patients with non-small cell lung cancer.